The role of positron emission tomography in the evaluation and staging of patients with recurrent colorectal carcinomas;Interet clinique de la tomographie a emission de positons dans la detection et le bilan d'extension des recidives des cancers colorectaux

Gastroenterologie Clinique et Biologique

Volumn 23, Issue 3, 1999, Pages 323-329

  Hustinx, Roland ^a   Paulus, Patrick ^b   Daenen, Frédéric ^b   Detroz, Bernard ^b   Honore, Pierre ^b   Jacquet, Nicolas ^b   Rigo, Pierre ^b  

^a UNIVERSITY OF LIÈGE   (Belgium)

^b NONE

Author keywords

18FDG; Colorectal cancer; CT scan; PET; Recurrent cancer; Staging

Indexed keywords

FLUORODEOXYGLUCOSE F 18;

ARTICLE; CANCER STAGING; COLORECTAL CARCINOMA; COMPUTER ASSISTED TOMOGRAPHY; CONTROLLED STUDY; DIAGNOSTIC APPROACH ROUTE; DIAGNOSTIC IMAGING; DIAGNOSTIC VALUE; HUMAN; LIVER METASTASIS; MAJOR CLINICAL STUDY; POSITRON EMISSION TOMOGRAPHY; TECHNIQUE; ADULT; AGED; COLON TUMOR; COMPUTER ASSISTED EMISSION TOMOGRAPHY; FEMALE; MALE; MIDDLE AGED; PATHOLOGY; RECTUM TUMOR; SCINTISCANNING; SENSITIVITY AND SPECIFICITY;

ADULT; AGED; COLONIC NEOPLASMS; FEMALE; HUMANS; MALE; MIDDLE AGED; NEOPLASM STAGING; RECTAL NEOPLASMS; SENSITIVITY AND SPECIFICITY; TOMOGRAPHY, EMISSION-COMPUTED;

EID: 0033014077     PISSN: 03998320     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (27)

1. Gore RM. Colorectal cancer. Clinical and pathologic features. Radiol Clin North Am 1997;35:403-29.
2. Mehta S, Johnson RJ, Schofield PF. Staging of colorectal cancer. Clin Radiol 1994;49:515-23.
3. Safi F, Link KH, Berger HG. Is follow-up of colorectal cancer patients worthwhile ? Dis Colon Rectum 1993;36:636-44.
4. Moertel CG, Fleming TRR, MacDonald JS, Haller DG, Laurie JA, Tangen C. An evaluation of the carcinoembryonic antigen (CEA) test for monitoring patients with resected colon cancer. JAMA 1993;270:943-7.
5. Vernava AM, Longo WE, Virgo KS, Coplin MA, Wade TP, Johnson FE. Current follow-up strategies after resection of colon cancer. Results of a survey of members of the American Society of Colon and Rectal Surgeons. Dis Colon Rectum 1994;37:573-83.
6. Steele G. Standard postoperative monitoring of patients after primary resection of colon and rectum cancer. Cancer 1993;71: 4225-35.
7. Kievit J, Bruinvels DJ. Detection of recurrence after surgery for colorectal cancer. Eur J Cancer 1995;31A : 1222-5.
8. Virgo KS, Vernava AM, Longo WE, McKirgan LW, Johnson FE. Cost of patient follow-up after potentially curative colorectal cancer treatment. JAMA 1995;273:1837-41.
9. Rigo P, Paulus P, Kaschten BJ, Hustinx R, Bury T, Jerusalem G, et al. Oncological applications of positron emission tomography with fluorine-18 fluorodeoxyglucose. Eur J Nucl Med 1996;23: 1641-74.
10. Wahl RL. Positron emission tomography : application in oncology. In : Murray ICP, EII PJ, eds. Nuclear Medicine, Clinical Diagnosis and Treatment. London : Churchill Livingstone. 1995, 801-20.
11. 18F-FDG in oncology : a clinical update. Nucl Med Biol 1996;23:717-35.
12. Warburg O, Wind F, Neglers E. On the metabolism of tumors in the body. In : Warburg O, ed. Metabolism of tumors. London : Constable, 1930:254-70.
13. Schlag P, Lehner B, Strauss LG, Georgi P, Herfarth C. Scar or recurrent rectal cancer. Positron emission tomography is more helpful for diagnosis than immunoscintigraphy. Arch Surg 1989;124:197-200.
14. Strauss LG, Clorius JH, Schlag P, Lehner B, Kimmig B, Engenhart R, et al. Recurrence of colorectal tumors : PET evaluation. Radiology 1989;170:329-32.
15. Vitola JV, Delbeke D, Sandler MP, Campbell MG, Powers TA, Wright JK, et al. Positron emission tomography to stage suspected metastatic colorectal carcinoma to the liver. Am J Surg 1996;171: 21-6.
16. Schiepers C, Penninckx F, De Vadder N, Merckx E, Mortelmans L, Bormans G, et al. Contribution of PET in the diagnosis of recurrent colorectal cancer : comparison with conventional imaging. Eur J Surg Oncol 1995;21:517-22.
17. Beets G, Penninckx F, Schiepers C, Mortelmans L, Kerremans R, Aerts R, et al. Clinical value of whole-body positron emission tomography with (18F)-fluorodeoxyglucose in recurrent colorectal cancer. Br J Surg 1994;81:1666-70.
18. Ito K, Kato T, Tadokoro M, Ishiguchi T, Oshima M, Ishigaki T, et al. Recurrent rectal cancer and scar : differentiation with PET and MR imaging. Radiology 1992;182:549-52.
19. Valk PE, Pounds TR, Tesar RD, Hopkins DM, Haseman MK. Cost-effectiveness of PET imaging in clinical oncology. Nucl Med Biol 1996;23:737-43.
20. 18F-fluorodeoxyglucose in identifying operable colorectal cancer metastases of the liver. Arch Surg 1996;131: 703-7.
21. Blend MJ, Abdel-Nabi H. New methods for the staging of colorectal cancer using noninvasive techniques. Semin Surg Oncol 1996;12:253-63.
22. Delbeke D, Vitola JV, Sandler MP, Arildsen RC, Powers TA, Wright JK, et al. Staging recurrent metastatic colorectal carcinoma with PET. J Nucl Med 1997;38:1196-201.
23. Beckers C, Paulus P, Rigo P. Evaluation abdomino-pelvienne des cancers ovariens : comparaison de la lomographie à émission de positons au 18-FDG avec la laparotomie exploratrice. Med Nucl Imag Fonct Metab 1996;20:479.
24. Higashi K, Seki H, Taniguchi M, et al. Bronchioloalveolar carcinoma : false-negative results on FDG-PET (abstract). J Nucl Med 1997;38 (Suppl.) : 79P.
25. Kinkel K, Tardivon AA, Soyer P, Spatz A, Lasser P, Rougier P, et al. Dynamic contrast-enhanced subtraction versus T2-weighted spin-echo MR imaging in the follow-up of colorectal neoplasm : a prospective study of 41 patients. Radiology 1996;200:453-8.
26. Karp JS, Muehllehner G, Qu H, Yan XH. Singles transmission in volume-imaging PET with a 137 Cs source. Phys Med Biol 1995;40:929-44.
27. Cook GJR, Fogelman I, Maisey MN. Normal physiological and benign pathological variants of 18-fluoro-2-deoxyglucose positron-emission tomography scanning : potential for error in interpretation. Semin Nucl Med 1996;26:308-14.